AU Patent

AU2022340824A1 — Methods and compositions for ameliorating biomarkers associated with cardiovascular risk using (r)-2-amino-3-phenylpropyl carbamate

Assigned to Axsome Therapeutics Inc · Expires 2024-02-29 · 2y expired

What this patent protects

The present invention provides methods for amelioration of biomarkers associated with cardiovascular risk with (R)-2-amino-3-phenylpropyl carbamate (APC).

USPTO Abstract

The present invention provides methods for amelioration of biomarkers associated with cardiovascular risk with (R)-2-amino-3-phenylpropyl carbamate (APC).

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

Patent Metadata

Patent number: AU2022340824A1
Jurisdiction: AU
Classification: —
Expires: 2024-02-29
Drug substance claim: No
Drug product claim: No
Assignee: Axsome Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.